Exhibit 99.1
FOR IMMEDIATE RELEASE
Compugen Reports Fourth Quarter and Full Year 2024 Results
| • |
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody
|
| • |
On track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2
2025
|
| • |
The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody
licensed to Gilead
|
| • |
Partner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers
and plans to share early data for rilvegostomig in combination with their ADCs in 2025
|
| • |
Solid financial position with cash runway expected to fund operations into 2027
|
HOLON, ISRAEL, March 4, 2025 - Compugen Ltd.
(Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2024 and provided a corporate update.
“I believe Compugen is well-positioned for growth, building on significant progress made in 2024 together with a diverse and innovative
pipeline and with a strong focus on execution in 2025,” said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “The clinical data we presented at SITC 2024, consistent with previous data, support advancing our potential first-in-class
anti-PVRIG, COM701, to be evaluated as a maintenance treatment option for patients with platinum sensitive ovarian cancer. We are on track to initiate an adaptive platform trial, which is scheduled to start with a randomized placebo controlled
sub-trial evaluating single agent COM701 therapy in Q2 2025. This development path is supported by a strong clinical and biological rationale and has the potential to open the door to advance COM701 as a single agent and as a backbone to future drug
combinations.”
Dr. Cohen-Dayag continued, “We are also encouraged by the promising rilvegostomig data presented by our partner, AstraZeneca, in 2024.
Rilvegostomig is a PD-1/TIGIT bispecific antibody, the TIGIT component of which is derived from COM902. AstraZeneca is running seven Phase 3 trials with rilvegostomig across lung and gastrointestinal cancers and plans to share early data for
rilvegostomig in combination with their ADCs in 2025. AstraZeneca’s broad development strategy for rilvegostomig to replace existing PD-1/PD-L1 inhibitors represents a significant potential revenue source for Compugen as we may be eligible for both
future milestone payments and mid-single digit tiered royalties on future sales.
Dr. Cohen-Dayag added, “Our solid financial position with a cash runway expected to fund our operations into 2027 allows us to advance
our innovative clinical and early-stage pipeline. This includes advancing the Phase 1 trial of GS-0321, a potential first-in-class anti-IL18BP licensed to Gilead, for which we received a $30 million milestone payment for achieving IND clearance in
2024. Additionally, it enables us to continue to leverage our AI/ML powered predictive computational discovery platform, UnigenTM, to accelerate our research efforts supporting our early pipeline. Our Unigen platform is validated by our
multiple potential first-in-class and potential best-in-class clinical programs, as well as our partnerships with AstraZeneca and Gilead.”
Next Planned Milestones
| • |
Q2 2025 – initiation of a randomized adaptive platform trial
comparing COM701 maintenance therapy to placebo in total of 60 patients with relapsed platinum sensitive ovarian cancer
|
| • |
2025 – Compugen’s partner, AstraZeneca, plans to share early
data for rilvegostomig in combination with their ADCs
|
| • |
H2 2026 – data from projected interim analysis of single agent
COM701 sub-trial 1 as maintenance therapy in relapsed platinum sensitive ovarian cancer
|
Fourth Quarter and Full Year 2024 Financial Highlights
Cash: As of December 31, 2024,
Compugen had approximately $103.3 million in cash, cash equivalents, short-term bank deposits and investment in marketable securities. The cash balance at the end of 2024 includes the receipt of the upfront payment of $60 million from Gilead for the
licensing of GS-0321, the $30 million milestone payment from Gilead for IND clearance (both subject to a 15% withholding tax) and the $15 million milestone payments from AstraZeneca on dosing of the first patient in the first and second major
indications for rilvegostomig Phase 3 trials.
In January and February 2025, subsequent to the financial results for the year ended December 31, 2024, a total of approximately 3.96
million shares were sold through the Company’s ATM facility contributing net proceeds of approximately $8.87 million (net of $274 thousand commission issuance expenses).
Compugen expects that its current cash will be sufficient to fund its operating plans into 2027. The Company has no debt.
Revenues: Compugen reported
approximately $1.5 million in revenues for the fourth quarter of 2024 and $27.9 million in revenues for the year ended December 31, 2024, compared to approximately $33.5 million in revenues for each of the comparable periods in 2023. The revenues for
2024 include the portion of the upfront payment and the IND milestone payment from the license agreement with Gilead and the $5 million clinical milestone payment from AstraZeneca, while the revenues for 2023 reflect the portion of the upfront
payment from the license agreement with Gilead allocated to the license and the previous clinical milestone from the license agreement with AstraZeneca in the amount of $10 million.
Cost of Revenues for the fourth
quarter and year ended December 31, 2024, were approximately $0.7 million and $7.9 million, respectively, compared with approximately $2.0 million for both comparable periods in 2023. Cost of revenues for 2024 represents the cost of IND and Phase 1
activities and royalty payments in connection with Compugen’s revenues, offset by royalty reversal in 2024 due to exemption received from the Israeli Innovation Authority from the requirement to pay royalties on income derived from sales associated
with products related to IL-18BP, while cost of revenues for 2023 represents milestone and royalty payments in connection with our revenues.
R&D expenses for the fourth
quarter and year ended December 31, 2024, decreased to approximately $5.9 million, and $24.8 million, respectively, compared with approximately $10.9 million and $34.5 million for the comparable periods in 2023, respectively. The decrease in 2024 was
mainly due to the classification of expenses related to GS-0321 to cost of revenues and to lower CMC and IND enabling activities related to GS-0321, partially offset by an increase in clinical expenses.
G&A expenses for the fourth
quarter and year ended December 31, 2024, were approximately $2.2 million and $9.4 million, respectively, compared with approximately $2.5 million and $9.7 million for the comparable periods in 2023, respectively.
Net Income / Loss: During the
fourth quarter of 2024, Compugen reported a net loss of approximately $6.1 million, or approximately 7 cents per basic and diluted share, compared to a net income of approximately $9.7 million, or approximately 11 cents per basic and diluted share in
the comparable period of 2023. Net loss for the year ended December 31, 2024, was approximately $14.2 million, or approximately 16 cents per basic and diluted share, compared with a net loss of approximately $18.8 million, or approximately 21 cents
per basic and diluted share in the comparable period in 2023.
Full financial tables are included below.
Conference Call and Webcast Information
The Company will hold a conference call today, March 4, 2025, at 8:30 AM ET to review its fourth quarter and full year 2024 results. To
access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational
discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody,
COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody,
which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Forward-Looking Statement To be updated
This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange
Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements
can be identified using terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” “confident,” and “intends,” and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statement regarding our expectations regarding the advancements of COM701 as a single
agent and as a backbone to future drug combinations; statements regarding the initiation of a randomized adaptive platform trial comparing COM701 maintenance therapy to placebo in total of 60 patients with relapsed platinum sensitive ovarian cancer
as well as the timing of any interim results from such sub-trial; statements regarding the timing of any data announcement by AstraZeneca regarding the combination of rilvegostomig with their ADCs; statements to the effect that our cash and
cash-related balances will be sufficient to fund our operating plans into 2027; and statements that our cash position will enable us to continue to leverage our AI/ML powered predictive computational discovery platform, Unigen, to accelerate our
research efforts supporting our early pipeline. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to
satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product
candidates; Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model;
Compugen’s approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen
operates, including Israel; the effect of the evolving nature of the recent war in Israel; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These risks
and other risks are more fully discussed in the “Risk Factors” section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements unless required by law.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
|
COMPUGEN LTD.
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
(U.S. dollars in thousands, except for share and per share amounts)
|
| |
|
Three Months Ended
|
|
|
Year Ended,
|
|
| |
|
December 31,
|
|
|
December 31,
|
|
| |
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
| |
|
Unaudited
|
|
|
Unaudited
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
1,471
|
|
|
|
33,459
|
|
|
|
27,864
|
|
|
|
33,459
|
|
|
Cost of revenues
|
|
|
675
|
|
|
|
2,004
|
|
|
|
7,930
|
|
|
|
2,004
|
|
|
Gross profit
|
|
|
796
|
|
|
|
31,455
|
|
|
|
19,934
|
|
|
|
31,455
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
5,911
|
|
|
|
10,928
|
|
|
|
24,810
|
|
|
|
34,472
|
|
|
Marketing and business development expenses
|
|
|
167
|
|
|
|
61
|
|
|
|
576
|
|
|
|
244
|
|
|
General and administrative expenses
|
|
|
2,201
|
|
|
|
2,482
|
|
|
|
9,439
|
|
|
|
9,731
|
|
|
Total operating expenses
|
|
|
8,279
|
|
|
|
13,471
|
|
|
|
34,825
|
|
|
|
44,447
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit (loss)
|
|
|
(7,483
|
)
|
|
|
17,984
|
|
|
|
(14,891
|
)
|
|
|
(12,992
|
)
|
|
Financial and other income, net
|
|
|
1,370
|
|
|
|
735
|
|
|
|
5,182
|
|
|
|
3,208
|
|
|
Profit (loss) before taxes on income
|
|
|
(6,113
|
)
|
|
|
18,719
|
|
|
|
(9,709
|
)
|
|
|
(9,784
|
)
|
|
Tax expense
|
|
|
4
|
|
|
|
9,006
|
|
|
|
4,522
|
|
|
|
8,970
|
|
|
Net profit (loss)
|
|
|
(6,117
|
)
|
|
|
9,713
|
|
|
|
(14,231
|
)
|
|
|
(18,754
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net earnings (loss) per ordinary share
|
|
|
(0.07
|
)
|
|
|
0.11
|
|
|
|
(0.16
|
)
|
|
|
(0.21
|
)
|
|
Weighted average number of ordinary shares used in computing basic and diluted net earnings (loss) per share
|
|
|
89,538,891
|
|
|
|
88,415,382
|
|
|
|
89,528,031
|
|
|
|
87,633,298
|
|
|
COMPUGEN LTD.
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
|
|
(U.S. dollars, in thousands)
|
| |
|
December 31,
|
|
|
December 31,
|
|
| |
|
2024
|
|
|
2023
|
|
| |
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
18,229
|
|
|
|
13,890
|
|
|
Restricted cash
|
|
|
-
|
|
|
|
365
|
|
|
Short-term bank deposits
|
|
|
61,397
|
|
|
|
25,053
|
|
|
Investment in marketable securities
|
|
|
23,629
|
|
|
|
11,742
|
|
|
Trade receivables
|
|
|
-
|
|
|
|
61,000
|
|
|
Other accounts receivable and prepaid expenses
|
|
|
2,742
|
|
|
|
2,529
|
|
|
Total current assets
|
|
|
105,997
|
|
|
|
114,579
|
|
| |
|
|
|
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
|
|
|
|
Restricted long-term bank deposit
|
|
|
343
|
|
|
|
-
|
|
|
Long-term prepaid expenses
|
|
|
1,888
|
|
|
|
1,233
|
|
|
Severance pay fund
|
|
|
3,072
|
|
|
|
2,977
|
|
|
Operating lease right to use asset
|
|
|
2,843
|
|
|
|
1,329
|
|
|
Property and equipment, net
|
|
|
852
|
|
|
|
1,216
|
|
|
Total non-current assets
|
|
|
8,998
|
|
|
|
6,755
|
|
| |
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
114,995
|
|
|
|
121,334
|
|
| |
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
|
Other accounts payable, accrued expenses and trade payables
|
|
|
10,080
|
|
|
|
14,485
|
|
|
Short-term deferred revenues
|
|
|
9,632
|
|
|
|
11,149
|
|
|
Current maturity of operating lease liability
|
|
|
448
|
|
|
|
632
|
|
|
Total current liabilities
|
|
|
20,160
|
|
|
|
26,266
|
|
| |
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
|
|
|
Long-term deferred revenues
|
|
|
34,045
|
|
|
|
25,392
|
|
|
Long-term operating lease liability
|
|
|
2,464
|
|
|
|
719
|
|
|
Accrued severance pay
|
|
|
3,412
|
|
|
|
3,398
|
|
|
Total non-current liabilities
|
|
|
39,921
|
|
|
|
29,509
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders' equity
|
|
|
54,914
|
|
|
|
65,559
|
|
| |
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
|
114,995
|
|
|
|
121,334
|
|